Kendall Capital Management Has $902,000 Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Kendall Capital Management decreased its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,449 shares of the specialty pharmaceutical company’s stock after selling 200 shares during the quarter. Kendall Capital Management’s holdings in Jazz Pharmaceuticals were worth $902,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Allspring Global Investments Holdings LLC grew its position in shares of Jazz Pharmaceuticals by 0.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 16,082 shares of the specialty pharmaceutical company’s stock worth $1,937,000 after buying an additional 99 shares during the period. ProShare Advisors LLC grew its position in shares of Jazz Pharmaceuticals by 1.4% during the 1st quarter. ProShare Advisors LLC now owns 7,439 shares of the specialty pharmaceutical company’s stock worth $896,000 after buying an additional 105 shares during the period. Ontario Teachers Pension Plan Board grew its position in shares of Jazz Pharmaceuticals by 0.4% during the 4th quarter. Ontario Teachers Pension Plan Board now owns 29,749 shares of the specialty pharmaceutical company’s stock worth $3,659,000 after buying an additional 108 shares during the period. Pinnacle Associates Ltd. grew its position in shares of Jazz Pharmaceuticals by 1.1% during the 1st quarter. Pinnacle Associates Ltd. now owns 10,371 shares of the specialty pharmaceutical company’s stock worth $1,249,000 after buying an additional 110 shares during the period. Finally, GAMMA Investing LLC grew its position in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after buying an additional 116 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Insider Buying and Selling

In related news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now owns 14,531 shares of the company’s stock, valued at approximately $1,573,707.30. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 4.20% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They issued a “buy” rating and a $169.00 price target for the company. Wells Fargo & Company reduced their price target on shares of Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Morgan Stanley reduced their price target on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research report on Friday, July 12th. Finally, Robert W. Baird reduced their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research report on Thursday, August 1st. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.07.

Jazz Pharmaceuticals Trading Down 1.8 %

NASDAQ JAZZ opened at $109.57 on Thursday. The stock has a market capitalization of $6.91 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 1.31 and a beta of 0.57. Jazz Pharmaceuticals plc has a one year low of $99.06 and a one year high of $137.38. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. The business’s fifty day moving average is $110.58 and its 200-day moving average is $111.14.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $3.80 by $0.87. The company had revenue of $1.02 billion for the quarter, compared to analysts’ expectations of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. Equities research analysts predict that Jazz Pharmaceuticals plc will post 16.03 EPS for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.